C4 Therapeutics, Inc.

CCCCNASDAQ • USD
2.65 USD
↘ 0.11 (3.99%)AT CLOSE (03:59 PM EST)
2.67
↗ 0.02 (0.72%)
POST MARKET (AS OF 07:56 PM EST)
Post Market
AS OF 07:56 PM EST
2.67
↗ 0.02 (0.72%)
🟢Market: OPEN

C4 Therapeutics, Inc. (CCCC) is currently trading at $2.67. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On valuation, CCCC trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Nov 16, 2026.

Open?$2.72
High?$2.76
Low?$2.59
Prev. Close?$2.76
Volume?3.1M
Avg. Volume?2.9M
VWAP?$2.66
Rel. Volume?1.08x
Bid / Ask
Bid?$2.23 × 100
Ask?$3.01 × 100
Spread?$0.78
Midpoint?$2.62
Valuation & Ratios
Market Cap?362.4M
Shares Out?131.3M
Float?98.5M
Float %?88.8%
P/E Ratio?N/A
P/B Ratio?1.59
EPS?-$0.69
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
Employees
104
Market Cap
362.4M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2020-10-02
Address
490 ARSENAL WAY
WATERTOWN, MA 02472
Phone: (617) 231-0700
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
0
Momentum?
77
Short Sent.?
5
Piotroski F-Score?2/9Weak
Altman Z-Score?-1.61Distress
Confidence?53%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?47.27%Squeeze Risk
Short Interest?46.6M
Days to Cover?15.1
Free Float98.5M
Avg Daily Volume3.1M
Settlement Date2026-10-30
Financial Health
Current Ratio?5.17Strong
Quick Ratio?5.17Strong
Cash Ratio?0.78Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
85
1.59CHEAP▾
P/S?
Peers
100
S&P
6
11.23HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.3CHEAP▾
EV/Sales?
Peers
100
S&P
10
10.22HIGH▾
Returns & Efficiency
ROE?
S&P
3
-39.9%WEAK▾
ROA?
S&P
3
-27.5%WEAK▾
Cash Flow & Enterprise
FCF?$-79741000
Enterprise Value?$330.0M
Fundamentals ratios updated end of day